4//SEC Filing
Miller Steve 4
Accession 0001161697-25-000420
CIK 0001369568other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 8:08 PM ET
Size
12.1 KB
Accession
0001161697-25-000420
Insider Transaction Report
Form 4
Miller Steve
VP Development & Management
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2025-11-21+8,267→ 1,067,930 total - Award
Options to purchase common stock
2025-11-20+158,454→ 1,457,963 totalExercise: $22.77Exp: 2032-11-20→ Common Stock (158,454 underlying) - Award
Restricted Stock Units
2025-11-20+47,826→ 1,489,255 total→ Common Stock (47,826 underlying) - Exercise/Conversion
Restricted Stock Units
2025-11-21−8,267→ 1,497,522 total→ Common Stock (8,267 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027, and 1/3rd on November 20, 2028.
- [F3]Shares of common stock will be delivered to the Reporting Person upon vesting.
- [F4]Derivative securities vest in three equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
- [F5]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001402535
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 8:08 PM ET
- Size
- 12.1 KB